These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26779268)

  • 1. The expression of CK-19 gene in circulating tumor cells of blood samples of metastatic breast cancer women.
    Soltani S; Mokarian F; Panjehpour M
    Res Pharm Sci; 2015; 10(6):485-96. PubMed ID: 26779268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
    Park HS; Han HJ; Lee S; Kim GM; Park S; Choi YA; Lee JD; Kim GM; Sohn J; Kim SI
    Yonsei Med J; 2017 Jan; 58(1):19-26. PubMed ID: 27873491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.
    Spiliotaki M; Mavroudis D; Kokotsaki M; Vetsika EK; Stoupis I; Matikas A; Kallergi G; Georgoulias V; Agelaki S
    Mol Oncol; 2018 Jan; 12(1):21-32. PubMed ID: 28766847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Time qPCR-Based Detection of Circulating Tumor Cells from Blood Samples of Adjuvant Breast Cancer Patients: A Preliminary Study.
    Andergassen U; Zebisch M; Kölbl AC; König A; Heublein S; Schröder L; Hutter S; Friese K; Jeschke U
    Breast Care (Basel); 2016 Jun; 11(3):194-8. PubMed ID: 27493620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy.
    Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H
    Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
    Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
    J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
    Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
    J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
    BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
    Kallergi G; Tsintari V; Sfakianakis S; Bei E; Lagoudaki E; Koutsopoulos A; Zacharopoulou N; Alkahtani S; Alarifi S; Stournaras C; Zervakis M; Georgoulias V
    Breast Cancer Res; 2019 Aug; 21(1):86. PubMed ID: 31370904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The detection of circulating breast cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction.
    Bae JW; Choi KH; Kim HG; Park SH
    J Korean Med Sci; 2000 Apr; 15(2):194-8. PubMed ID: 10803697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis.
    Wang JY; Wu CH; Lu CY; Hsieh JS; Wu DC; Huang SY; Lin SR
    World J Surg; 2006 Jun; 30(6):1007-13. PubMed ID: 16736329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating tumor cells in metastatic breast cancer patients.
    Sanislo L; Vertakova-Krakovska B; Kuliffay P; Brtko J; Galbava A; Galbavy S
    Endocr Regul; 2011 Jul; 45(3):113-24. PubMed ID: 21793623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
    Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
    Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.